Bullish
Eli Lilly's Foundayo captures over 30% of new U.S. oral weight-loss patients
Eli Lilly's oral obesity treatment, Foundayo, has secured more than 30% of new patients in the U.S. market, narrowing the lead of competitor Novo Nordisk's Wegovy. This significant market share gain underscores Foundayo's growing acceptance among patients seeking oral weight-loss solutions.
Key points
- Foundayo's rapid adoption in the U.S. oral weight-loss market.
- Berenberg upgrades Eli Lilly to 'Buy' with a $1,400 price target.
- Eli Lilly to present new data at EASD 2026 on Foundayo and other therapies.
Sources
AI-generated from public news sources. Not financial advice.
